Argenx SeARGX
Price (close)
$959.49
Market cap
$59.4B
P/E
46.0x
Revenue (FY)
$4.2B
Net income
$1.3B
Dividend yield
—
1-year total return
34.9%
Net margin
30.4%
Revenue growth
88.6%
Debt / equity
—
What Argenx Se does.
incorporation until August 28, 2009, our research and development activities were initially performed in the Netherlands,
the legal ownership of all intellectual property rights of argenx SE to argenx BV, effective retroactively as of January 1,
strengthened our position as the #1 prescribed and fastest‑growing biologic, supported by increasingly earlier use in the
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $41.2M | $497.3M | $10.0M | $35.5M | $2.3B | $4.2B |
| Net income | -$608.5M | -$408.3M | -$709.6M | -$295.1M | $833.0M | $1.3B |
| Free cash flow | -$399.5M | -$610.4M | -$863.6M | -$421.1M | -$84.5M | $679.0M |
More on ARGX.
- Argenx Se summary
- Argenx Se financial statements
- Argenx Se key metrics
- Argenx Se health scores and style box
- Argenx Se earnings
- Argenx Se dividends
- Argenx Se valuation
- Argenx Se ownership and insiders
- Argenx Se peers
Figures from Argenx Se's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.